Posts Tagged ‘pharma’

  Over the past few months, the life sciences practice has produced several free resources related to the 21 CFR Part 11 regulation that governs electronic records and electronic signatures. To make it easy for our industry colleagues to find those resources, we decided to create a single blog post that links to all of […]

  One of the most common questions we hear from clients is “What file formats can Google Search Appliance (GSA) index?” Since so many people are curious, we decided to share the answer with you in our blog. It goes a little something like this: The number of file formats GSA can index is incredible. […]

  Back in April, I wrote the piece 5 Apps Leveraging Apple’s ResearchKit For Clinical Studies. What’s interesting, in retrospect, is that none of those apps were developed by pharmaceutical companies, but rather by academic medical centers and nonprofit organizations. 

  Now that August is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in July – they’re ranked in order of popularity, with number one being the most viewed piece. 

<   The work we’re doing for life sciences and healthcare companies continues to pay off. And, Oracle thinks so, too. We recently received an award from Oracle’s Health Sciences Global Business Unit for the work we’re doing with their clinical and pharmacovigilance applications. 

One of my LinkedIn contacts shared the video Risk-Based Monitoring vs Remote Monitoring Finally Explained, in which Dan Sfera of www.theclinicaltrialsguru.com explains both concepts in layman’s terms. In essence, the idea of Risk-Based Monitoring (RBM) is to leverage the data in existing IT systems to spot, rectify, and prevent issues relating to the execution of […]

  I’ve been taking omeprazole for at least 10 years. Every day. Sometimes more than one day…but only by accident. I didn’t like the fact that I couldn’t remember whether I took a pill in the morning, which would sometimes lead me to take an additional pill that may have not been necessary. That’s why […]

  Several months ago we delivered a webinar on 21 CFR Part 11, based on a recent blog series. During the Q&A session at the end, someone asked the following question: Regarding “the organization” that needs to inform the FDA of the intended use of electronic signatures, in a CRO/Sponsor relationship, who is responsible: the […]

Editorial Credit: Gil C / Shutterstock.com Analyzing Google searches to uncover previously unknown adverse events isn’t news, per se, but it looks like it could be gaining traction with the FDA. According to a recent Bloomberg article, the FDA’s public calendar shows that several employees from Google met with the FDA to discuss the possibility […]

  When you think of a pharmaceutical companies, you think drugs. You think of them as a business – drugs being developed, sold, and consumed. Not often do you think of them as do-gooders. 

  According to analysts from Credit Suisse, the prices of brand name drugs are significantly increasing, due to fast-approaching patent expiration dates and the desire to capitalize on recent approvals. Of the 140 drugs the company tracks, 43 have had a price increase in the second quarter of 2015, setting a record for the most […]

  Most of us “regular people” refer to pharmaceutical products by their trade name, but that’s not the case among life sciences professionals in research and development departments. In fact, during a product’s lifecycle, chances are it has been referred to by at least four names: a chemical compound, a company code, a generic name, […]